AVEO PHARMACEUTICALS, INC. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Revenues
Collaboration and Licensing Revenue
FOTIVDA U.S. product revenue, net
Partnership licensing and royalty revenue
Total revenues
Operating expenses:
Cost of products sold
Research and development
Selling, general and administrative
Settlement costs
Operating expenses

Loss from operations
Other income (expense), net:
Interest expense, net
Change in fair value of PIPE Warrant liability
Other income
Other income (expense), net
Net income (loss) before provision for income taxes
Provision for income taxes
Net income (loss)
Net loss per share
Weighted average number of common shares outstanding
Basic net income (loss) per share
Net income (loss) per share (in dollars per share)
Weighted average number of common shares outstanding (in shares)
Diluted net income (loss) per share
Net income (loss) per share (in dollars per share)
Weighted average number of common shares outstanding (in shares)

Comments